|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
4
|
Resverlogix Corp.
|
Mar 24, 2020 05:00PM
|
|
SARS-CoV-2 and BRD interactions
|
6
|
Resverlogix Corp.
|
Mar 24, 2020 05:56PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
9
|
Resverlogix Corp.
|
Mar 26, 2020 01:10PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
8
|
Resverlogix Corp.
|
Mar 26, 2020 02:36PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
6
|
Resverlogix Corp.
|
Mar 26, 2020 02:55PM
|
|
Re: RAAS Inhibitors in Patients with Covid-19
|
4
|
Resverlogix Corp.
|
Mar 31, 2020 10:58AM
|
|
Re: DM Interview w Jane King (Innovators) Apr 7 - COVID 19
|
12
|
Resverlogix Corp.
|
Apr 09, 2020 12:11AM
|
|
Re: Random thoughts RVX-208 and COVID-19
|
6
|
Resverlogix Corp.
|
Apr 12, 2020 09:47PM
|
|
Presentation available
|
2
|
Resverlogix Corp.
|
Jun 10, 2020 10:47AM
|
|
Re: BOM 2 Trial
|
5
|
Resverlogix Corp.
|
Jun 10, 2020 12:12PM
|
|
Re: Apabetalone recudes ALP (apologies if repeat. looked on the new side)
|
9
|
Resverlogix Corp.
|
Jun 11, 2020 12:30AM
|
|
Re: Apabetalone recudes ALP (apologies if repeat. looked on the new side)
|
3
|
Resverlogix Corp.
|
Jun 12, 2020 12:23AM
|
|
Re: Still waiting for that BETonMACE CKD sub-study 7 months later
|
8
|
Resverlogix Corp.
|
Jun 12, 2020 02:15PM
|
|
ACE2 and Covid
|
8
|
Resverlogix Corp.
|
Sep 25, 2020 11:05AM
|
|
Re: ACE2 and Covid....Link to the Lancet article:
|
3
|
Resverlogix Corp.
|
Sep 25, 2020 12:29PM
|
|
Re: ACE2 and Covid
|
2
|
Resverlogix Corp.
|
Sep 25, 2020 06:29PM
|
|
Re: Rules of thumb and broken thumbs...
|
9
|
Resverlogix Corp.
|
Sep 29, 2020 03:47PM
|
|
shareholder participation in share issuance
|
1
|
PyroGenesis Canada Inc
|
Oct 15, 2020 11:18PM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
8
|
Resverlogix Corp.
|
Nov 02, 2020 06:37PM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
3
|
Resverlogix Corp.
|
Nov 02, 2020 10:15PM
|
